Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature-Reference-Cited by-同舟云学术

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

Published:2020-02-20 Issue:2 Volume:33 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Corneli Paola¹^ORCID,Conforti Claudio¹^ORCID,Retrosi Chiara¹,Vezzoni Roberta¹,Meo Nicola¹,Piccolo Vincenzo²^ORCID,Farinazzo Eleonora¹,Russo Teresa²,Magaton Rizzi Giovanni¹,Giuffrida Roberta³^ORCID,Zalaudek Iris¹

Affiliation:

1. Dermatology Unit Maggiore Hospital Trieste, University of Trieste Trieste Italy

2. Dermatology Unit Second University of Naples Naples Italy

3. Clinical and Experimental Medicine University of Messina Messina Italy

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.13250

Reference51 articles.

1. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies

2. Unresectable Cutaneous Squamous Cell Carcinoma of the Forehead With MLH1 Mutation Showing Dramatic Response to Programmed Cell Death Protein 1 Inhibitor Therapy

3. Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

4. Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature

5. Nivolumab for recurrent cutaneous squamous cell carcinoma: Three cases;Blum V.;European Journal of Dermatology,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of Non-Melanoma Skin Cancers in Salento (Southern Italy): A 15-Year Retrospective Analysis from the Cancer Registry of Lecce;Epidemiologia;2023-12-21

2. Dichotomic response patterns to PD ‐1 blockade with cemiplimab in a patient with multiple squamous cell carcinomas;Journal of the European Academy of Dermatology and Venereology;2022-11-07

3. Cemiplimab for metastatic squamous cell carcinoma of the orbit, periocular adnexa, and thigh;Orbit;2022-09-02

4. Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response;Journal of Clinical Medicine;2022-06-11

5. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel;Expert Review of Anticancer Therapy;2021-02-07